Ayala Pharmaceuticals announced preliminary results from its ongoing Phase 2 ACCURACY study of lead investigational new drug candidate, AL101, in patients with recurrent/metastatic adenoid cystic carcinoma (ACC) with progressing disease and Notch activating mutations.
Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients
